nodes	percent_of_prediction	percent_of_DWPC	metapath
Clidinium—CHRM1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.027	0.0277	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.027	0.0276	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0265	0.0271	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0264	0.027	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0227	0.0233	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0227	0.0232	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0223	0.0228	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0222	0.0227	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0161	0.0164	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.016	0.0164	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0154	0.0158	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0154	0.0157	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0149	0.0153	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0149	0.0152	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0145	0.0148	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0144	0.0147	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0142	0.0145	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0142	0.0145	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.014	0.0144	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.014	0.0143	CbGpPWpGaD
Clidinium—CHRM3—Regulation of insulin secretion—ADRA2C—attention deficit hyperactivity disorder	0.0137	0.014	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0135	0.0138	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0135	0.0138	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0131	0.0134	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.013	0.0133	CbGpPWpGaD
Clidinium—Diphenylpyraline—SLC6A3—attention deficit hyperactivity disorder	0.0126	0.566	CrCbGaD
Clidinium—CHRM1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0125	0.0128	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0125	0.0128	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0122	0.0124	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0121	0.0124	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0119	0.0122	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0119	0.0122	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0118	0.0121	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0118	0.012	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.011	0.0112	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.011	0.0112	CbGpPWpGaD
Clidinium—CHRM3—Integration of energy metabolism—ADRA2C—attention deficit hyperactivity disorder	0.0108	0.011	CbGpPWpGaD
Clidinium—Benzatropine—SLC6A3—attention deficit hyperactivity disorder	0.00968	0.434	CrCbGaD
Clidinium—CHRM3—Regulation of insulin secretion—CACNB2—attention deficit hyperactivity disorder	0.00945	0.00966	CbGpPWpGaD
Clidinium—CHRM1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00916	0.00936	CbGpPWpGaD
Clidinium—CHRM3—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00913	0.00933	CbGpPWpGaD
Clidinium—CHRM3—Regulation of insulin secretion—CACNA1C—attention deficit hyperactivity disorder	0.00864	0.00884	CbGpPWpGaD
Clidinium—CHRM1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0077	0.00787	CbGpPWpGaD
Clidinium—CHRM3—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00767	0.00785	CbGpPWpGaD
Clidinium—CHRM3—Regulation of insulin secretion—SNAP25—attention deficit hyperactivity disorder	0.00755	0.00773	CbGpPWpGaD
Clidinium—CHRM3—Integration of energy metabolism—CACNB2—attention deficit hyperactivity disorder	0.00743	0.0076	CbGpPWpGaD
Clidinium—CHRM3—Regulation of insulin secretion—ADRA2A—attention deficit hyperactivity disorder	0.00719	0.00735	CbGpPWpGaD
Clidinium—CHRM3—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00679	0.00695	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Other—DRD3—attention deficit hyperactivity disorder	0.0064	0.00655	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Other—DRD4—attention deficit hyperactivity disorder	0.00621	0.00636	CbGpPWpGaD
Clidinium—CHRM3—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.00594	0.00607	CbGpPWpGaD
Clidinium—CHRM3—Integration of energy metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00565	0.00578	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00522	0.00534	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.0052	0.00532	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00511	0.00523	CbGpPWpGaD
Clidinium—CHRM1—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.00511	0.00523	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.0051	0.00521	CbGpPWpGaD
Clidinium—CHRM3—Calcium Regulation in the Cardiac Cell—CACNA1C—attention deficit hyperactivity disorder	0.0051	0.00521	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00508	0.00519	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00506	0.00518	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00447	0.00457	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00446	0.00456	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—TPH2—attention deficit hyperactivity disorder	0.0044	0.0045	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00438	0.00448	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00437	0.00447	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Other—HTR2A—attention deficit hyperactivity disorder	0.00405	0.00415	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00354	0.00363	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00353	0.00361	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—SLC6A4—attention deficit hyperactivity disorder	0.00352	0.0036	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—DRD1—attention deficit hyperactivity disorder	0.00352	0.0036	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—DRD3—attention deficit hyperactivity disorder	0.00341	0.00348	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00341	0.00348	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00339	0.00347	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00334	0.00341	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00333	0.0034	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—DRD4—attention deficit hyperactivity disorder	0.00331	0.00338	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0031	0.00317	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00309	0.00316	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—DRD2—attention deficit hyperactivity disorder	0.00308	0.00315	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00304	0.00311	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00303	0.0031	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00288	0.00295	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00287	0.00294	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00287	0.00293	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00286	0.00293	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00279	0.00285	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00278	0.00284	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00274	0.0028	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00273	0.0028	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00271	0.00277	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0027	0.00276	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00265	0.00271	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00265	0.00271	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00261	0.00267	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.0026	0.00266	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00252	0.00258	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00251	0.00257	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00247	0.00252	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00246	0.00252	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00239	0.00244	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00238	0.00244	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00235	0.0024	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00234	0.0024	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00232	0.00237	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00231	0.00237	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00231	0.00237	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00231	0.00236	CbGpPWpGaD
Clidinium—CHRM1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00229	0.00234	CbGpPWpGaD
Clidinium—CHRM3—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00228	0.00233	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00216	0.00221	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00215	0.0022	CbGpPWpGaD
Clidinium—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00204	0.00209	CbGpPWpGaD
Clidinium—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00204	0.00208	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00202	0.00207	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00201	0.00206	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00192	0.00197	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00192	0.00196	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00189	0.00193	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00188	0.00192	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00188	0.00192	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00187	0.00192	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00182	0.00186	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00181	0.00186	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00179	0.00183	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00178	0.00182	CbGpPWpGaD
Clidinium—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00177	0.00181	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00177	0.00181	CbGpPWpGaD
Clidinium—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00176	0.0018	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00176	0.0018	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00175	0.00179	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00174	0.00178	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00171	0.00175	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00171	0.00175	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00165	0.00168	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00164	0.00168	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00154	0.00157	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00153	0.00157	CbGpPWpGaD
Clidinium—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00151	0.00155	CbGpPWpGaD
Clidinium—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00151	0.00154	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00131	0.00134	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.0013	0.00133	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00123	0.00126	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0012	0.00123	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.0012	0.00123	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00119	0.00121	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00118	0.00121	CbGpPWpGaD
Clidinium—CHRM1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00115	0.00118	CbGpPWpGaD
Clidinium—CHRM3—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00115	0.00118	CbGpPWpGaD
Clidinium—CHRM1—Circadian rythm related genes—EP300—attention deficit hyperactivity disorder	0.00114	0.00117	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00114	0.00117	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00114	0.00116	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00106	0.00109	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00106	0.00108	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00104	0.00106	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00103	0.00106	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00103	0.00106	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00103	0.00105	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00103	0.00105	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00103	0.00105	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00101	0.00103	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00101	0.00103	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00101	0.00103	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00101	0.00103	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000998	0.00102	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000995	0.00102	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000992	0.00101	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000989	0.00101	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000964	0.000986	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000961	0.000983	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000934	0.000955	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000931	0.000952	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00093	0.000951	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000927	0.000948	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000918	0.000939	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000915	0.000936	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000907	0.000927	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000904	0.000924	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00085	0.000869	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00085	0.000869	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000845	0.000864	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000842	0.000861	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000836	0.000855	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000777	0.000795	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000701	0.000717	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000699	0.000715	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000679	0.000695	CbGpPWpGaD
Clidinium—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000651	0.000666	CbGpPWpGaD
Clidinium—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000649	0.000664	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000647	0.000661	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000613	0.000627	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000611	0.000625	CbGpPWpGaD
Clidinium—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000592	0.000605	CbGpPWpGaD
Clidinium—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.00059	0.000603	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.00057	0.000583	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000568	0.000581	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000552	0.000564	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00055	0.000563	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000542	0.000555	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000541	0.000553	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000536	0.000548	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000534	0.000546	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	0.000515	0.000526	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000511	0.000523	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000499	0.00051	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000497	0.000509	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000349	0.000357	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000348	0.000356	CbGpPWpGaD
Clidinium—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	0.000221	0.000226	CbGpPWpGaD
Clidinium—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000185	0.000189	CbGpPWpGaD
Clidinium—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000185	0.000189	CbGpPWpGaD
